CRISPR Therapeutics (NASDAQ: CRSP) is a clinical-stage gene-editing company best known for CASGEVY™ (exagamglogene autotemcel, or exa-cel), the first FDA-approved CRISPR-based therapy (co-commercialized with Vertex) for sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT). The near-term investment case hinges on the commercial ramp of CASGEVY, milestone/royalty economics from Vertex, and new in vivo programs—notably CTX310 (ANGPTL3) for cardio-metabolic disease, which posted positive Phase 1 data at AHA 2025—plus a rejuvenated allogeneic CAR-T franchise (CTX112/CTX131).
Company Snapshot
- Founded: 2013; HQ in Zug, Switzerland & Boston, MA
- Focus: CRISPR/Cas9 gene-editing to create one-time, potentially curative therapies across hemoglobinopathies, immuno-oncology, autoimmune, diabetes, and cardio-metabolic diseases.
- Flagship program: CASGEVY for SCD and TDT with Vertex leading global development, manufacturing, and commercialization; economics shared between the companies.
Vertex collaboration terms (high level): Vertex leads development and commercialization for exa-cel/CASGEVY; the partners amended economics to 60/40 (Vertex/CRISPR) on costs and profits. Vertex also paid a $200M milestone upon FDA approval (accounted for by Vertex as amortized cost of sales). These details matter for modeling CRISPR’s revenue line.
Why CRSP Now? 2025 Investment Context
- Commercial validation: CASGEVY launched commercially in late 2023; 2024–2025 brought first real-world infusions and a global rollout, with multiple markets coming online. Industry reporting flags material sequential sales growth in 2025 as the launch expands.
- Fresh pipeline upside: CTX310 (ANGPTL3) delivered deep, durable lipid lowering in Phase 1 (AHA 2025; NEJM publication), expanding CRISPR’s reach beyond rare disease into large cardio-metabolic markets.
- Optionality from oncology & autoimmune: Next-gen allogeneic CAR-T CTX112 (CD19) and CTX131 (CD70) aim to improve potency/safety over first-gen assets; peer-reviewed data on predecessor CTX130 de-risks the platform. CRISPR has also flagged autoimmune entry.
- Secular tailwinds: Gene-editing is moving mainstream. Big Pharma’s growing appetite (e.g., Lilly–Verve) and broader partnerships underscore category validation.
Stock Performance & Valuation Lens
CRSP has been volatile—typical of clinical/early commercial biotech. The market focuses on:
- CASGEVY patient flow (referrals → eligibility → apheresis → conditioning → infusion → follow-up) and payer access.
- Speed of international launches and center activations.
- Readouts from in vivo and CAR-T programs that could expand TAM and diversify revenues.
(Realtime quote/market cap displayed in the live widget above.)
Business Model & Revenue Drivers
1) Hemoglobinopathies (Commercial): CASGEVY (exa-cel)
- Indications: SCD and TDT; first US approval in December 2023, followed by additional regions. Vertex reports the launch is “picking up steam,” with first commercial infusions noted early in 2024 and continued momentum into 2025. Pricing in gene therapy is high per patient (varies by region), supporting material revenue leverage as throughput scales.
- Economics: Vertex/CRISPR 60/40 split on costs and profits; CRISPR also recognized a $200M approval milestone from Vertex (per Vertex IR accounting language). These profit-share terms, rather than simple royalties, can create operating leverage if manufacturing and logistics scale efficiently.
- Launch watch-items: manufacturing capacity, vein-to-vein timelines, center onboarding, payer contracting, and long-term durability/safety data sets for SCD/TDT.
2) In Vivo Gene Editing (Pipeline)
- CTX310 (ANGPTL3) — Positive Phase 1 results (AHA 2025; NEJM) show significant triglyceride and lipid reduction with deep, durable editing. This is a large-market shot on goal (heterozygous familial hypercholesterolemia, severe hypertriglyceridemia, atherosclerotic CVD risk reduction). Next steps likely include dose confirmation and Phase 2 design with regulators.
- Broader cardio-metabolic slate: Industry trackers also list Lp(a) and other metabolic targets under evaluation across the field, positioning CRISPR in a competitive but high-value space.
3) Allogeneic CAR-T (Oncology/Autoimmune)
- Transitioned from first-gen (CTX110/120/130) to next-gen programs CTX112 (CD19) and CTX131 (CD70) with improved potency edits and streamlined lymphodepletion. Peer-reviewed Lancet Oncology data for CTX130 support feasibility and safety of the approach. CRISPR also outlined autoimmune ambitions, leveraging similar immune-cell engineering know-how.
4) Diabetes Cell Therapy
- The legacy ViaCyte collaboration evolved; Vertex exited the joint program, and CRISPR took full ownership (now VCTX211/CTX211) of an immune-evasive, gene-edited pancreatic progenitor cell therapy delivered in a retrievable device. A Phase 1/2 study is recruiting. This is high-risk/high-reward and on a longer timeline, but the addressable market is substantial.
Financial Overview (through 2025 context)
- Earnings cadence: CRISPR reported Q2 2025 on Aug 4, 2025 and Q3 2025 on Nov 4, 2025 (per market data aggregators). Consensus tracked by financial portals anticipated higher revenues and an EPS loss narrowing in H2 as CASGEVY ramps and milestone accounting normalizes. Always cross-check the company’s 8-K/10-Q for GAAP detail and cash runway.
- Historical filings: The 2024 Form 10-K and the Feb 11, 2025 business update remain the best primary sources for cash, burn, and pipeline guidance. Use them to anchor your model assumptions (R&D trajectory, G&A, profit-share timing, and potential capital raises).
Modeling tip: For CASGEVY, build a center-level funnel (active centers × eligible patients × conversion × timing lag) and apply the 60/40 profit-share to vertex-reported net product revenue minus COGS/OPEX allocations. Adjust for geography-specific pricing/access.
Market Landscape & Competition
- Gene editing momentum: Pharma is buying or partnering selectively in CRISPR and base-editing—e.g., Lilly–Verve—signaling durable interest in one-time edits for cardiometabolic disease. This validates the CTX310 opportunity if efficacy/safety remain strong.
- Heme competition: Bluebird, Editas, and others target SCD/TDT with different modalities; execution (manufacturing/logistics), durability, and safety will differentiate outcomes.
- Oncology: Allogeneic CAR-T is competitive (Allogene, Caribou, Precision, etc.); CRISPR’s edge is multi-edit engineering and process design, but clinical data will decide.
Growth Catalysts (Next 6–18 Months)
- CASGEVY launch metrics: more authorized treatment centers, shorter vein-to-vein time, payer coverage expansions, international pricing decisions, and additional TDT uptake.
- In vivo readouts: Follow-up CTX310 durability/safety datasets; potential Phase 2 start. Watch for pipeline reveals around Lp(a) or adjacent metabolic targets.
- Oncology milestones: Updated CTX112/CTX131 data (ORR, CR rates, durability, manufacturing consistency). Peer-reviewed CTX130 data already provide platform support.
- Diabetes program updates: Enrollment progress and early signals from VCTX211/CTX211 first-in-human study.
- Corporate/BD: New partnerships outside hemoglobinopathies could bring non-dilutive cash and validation.
Key Risks
- Clinical & regulatory: In vivo editing (e.g., liver-directed CRISPR) demands pristine safety. Any SAE signals could delay programs. Allogeneic CAR-T remains competitive and technically challenging.
- Commercial execution: CASGEVY uptake depends on center throughput, patient selection, and payer logistics; one-time therapies create “bolus” rather than recurring revenues, complicating modeling.
- Financial: Sustained R&D investment with uneven milestone timing may require capital raises, especially if pipeline timelines extend. Use 10-K/10-Q to monitor runway and share count dynamics.
- Competition/IP: Rapid innovation by rivals (base editors, prime editors, or novel delivery) could compress CRISPR’s competitive window.
Investment Thesis & Scenarios
Base Case (constructive):
- CASGEVY continues a measured but accelerating ramp across SCD and TDT with increasing center productivity in 2025–2026; CRISPR recognizes its share of profits accordingly.
- CTX310 advances into mid-stage testing, maintaining a clean safety profile and meaningful lipid lowering—unlocking a large addressable cardio-metabolic market and attracting partnership interest.
- Next-gen CAR-T delivers clearer efficacy signals in defined sub-indications.
Bull Case:
- Faster-than-expected CASGEVY throughput (payer/center friction declines), strong ex-US adoption, and multi-indication expansion.
- CTX310 and a follow-on in vivo asset (e.g., Lp(a)) show best-in-class performance → premium partner deal and pipeline re-rating.
- CAR-T posts pivotal-quality outcomes in a niche lymphoma setting, creating another commercial vector.
Bear Case:
- Slower CASGEVY ramp due to logistics or payer pushback; in vivo safety flags or modest efficacy hamper expansion; CAR-T competition outpaces CRISPR’s next-gen assets.
How to Analyze CRSP Like a Pro (Checklist)
- Track Vertex KPIs each quarter: patient starts, infusions, centers active—then map to CRISPR’s 40% profit share.
- Read primary sources: CRISPR press releases/8-K/10-Q/10-K and clinical abstracts; avoid relying solely on secondary summaries.
- Follow medical meetings (AHA, ASH, ASCO, EAS) for in vivo and CAR-T updates—e.g., AHA 2025 for CTX310.
- Watch the competitive tape (e.g., Lilly–Verve) for read-through on payer/regulatory sentiment in cardio-metabolic gene editing.
FAQs
Is CASGEVY really first-in-class?
Yes—the first FDA-approved CRISPR-based therapy (Dec 2023), initially for SCD, with rollout broadening to TDT and other regions thereafter.
How does CRISPR get paid on CASGEVY?
Through a 60/40 cost and profit share with Vertex (Vertex leads). CRISPR also benefited from a $200M approval milestone upon FDA green light.
What’s the biggest 2025 pipeline news?
CTX310 (ANGPTL3) Phase 1 human data showed deep, durable lipid lowering (AHA 2025/NEJM), opening a path toward larger cardio-metabolic indications.
What happened to the diabetes alliance?
Vertex exited; CRISPR retained and is advancing VCTX211/CTX211 alone in a Phase 1/2 T1D study with an immune-evasive, gene-edited cell therapy + device.
What are the main risks?
Clinical safety in in vivo editing, commercial execution for one-time therapies, financing/market volatility, and intense competition from other editors and modalities.
Sources & Further Reading
- Nasdaq overview page for CRSP (baseline market context).
- Vertex–CRISPR collaboration terms and CASGEVY milestone disclosures (official IR).
- FDA/launch coverage and commercial infusion updates.
- AHA 2025 / NEJM positive CTX310 Phase 1 results (ANGPTL3 editing).
- CRSP filings/updates: 10-K (2024) and Feb 11, 2025 business update.
- Peer-reviewed oncology data for the allogeneic platform (CTX130).
- Macro validation: Lilly–Verve transaction (FT) and broader CRISPR partnerships (Reuters).
Bottom Line
CRISPR Therapeutics sits at a pivotal juncture: a first commercial asset (CASGEVY) providing real-world validation, a high-upside in vivo platform now with human proof-of-concept in cardio-metabolic disease, and maturing cell-therapy programs targeting oncology and autoimmune conditions. Execution on commercial scale-up and clean, repeatable clinical wins will determine whether CRSP transitions from a one-asset story into a multi-platform gene-editing leader.
XAUT-USD 
AMD 
JNJ 
MARA 
SHOP 
UNH 
BULL 
EURUSD=X 
CL=F